Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen Stock Is Surging Today: What's Going On? - Biogen (NASDAQ:BIIB)
09:16am, Wednesday, 30'th Nov 2022
Biogen Inc (NASDAQ: BIIB) shares are trading higher Wednesday after the company announced positive trial results for its experimental Alzheimer's
Eleven Stocks Turned $10,000 To $261,421 In 11 Months
08:00am, Wednesday, 30'th Nov 2022
Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.
Biogen stock up 3% premarket after update on Alzheimer's treatment; Stifel reiterates buy rating
06:48am, Wednesday, 30'th Nov 2022
Biogen Inc. stock BIIB, -0.17% rose 3% in premarket trade Wednesday, after a new study was unveiled late Tuesday that showed the company's experimental Alzheimer's drug being developed with Japan's Ei
Biogen and Eisai Strengthen Lead in Alzheimer's Drug Race. The Stocks Are Rising.
05:11am, Wednesday, 30'th Nov 2022
Shares in the pharmaceutical companies rose after the publication of a paper detailing the apparent benefits of lecanemab.
Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors
08:44pm, Tuesday, 29'th Nov 2022
Biogen stock was muted late Tuesday after Eisai unveiled Alzheimer's treatment results likely to spark a debate over the drug's benefits. The post Why This New Alzheimer's Update Is Likely To Spark A
New Alzheimer's drug slows decline in memory - fuelling hope doctors will one day cure dementia
08:09pm, Tuesday, 29'th Nov 2022
Doctors have hailed a "new era" of medicine after a study showed for the first time that a drug can slow the debilitating symptoms of Alzheimer's.
Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focus
07:55pm, Tuesday, 29'th Nov 2022
New data was presented on Tuesday.
Biogen (BIIB) Down on Report of Death in Alzheimer's Study
02:18pm, Tuesday, 29'th Nov 2022
Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.
Research Paper Reports Death in Biogen's Experimental Drug
09:37am, Monday, 28'th Nov 2022
Biogen Inc (NASDAQ:BIIB) is under pressure this morning, in the wake of a research paper published on Science.org this Sunday.
Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success
09:07am, Monday, 28'th Nov 2022
Biogen stock toppled Monday after a report suggested its experimental Alzheimer's treatment caused a patient's fatal brain hemorrhage. The post Biogen Dives On Reports Of Alzheimer's Death While Axsom
2 Stocks Near 52-Week Highs That Could Climb Higher
05:33am, Monday, 28'th Nov 2022
This pair of stocks are bucking the trend and they could climb even higher.
Why Is Biogen Inc. (BIIB) Up 8.2% Since Last Earnings Report?
12:47pm, Thursday, 24'th Nov 2022
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?
BIIB or RGEN: Which Is the Better Value Stock Right Now?
12:48pm, Wednesday, 23'rd Nov 2022
BIIB vs. RGEN: Which Stock Is the Better Value Option?
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned
Third FDA advisor resigns after Biogen's Alzheimer's drug approval
07:43am, Saturday, 19'th Nov 2022
A third FDA advisor has resigned following last week's controversial accelerated approval of Biogen's Alzheimer's drug.
